Long-Term Outcomes of Neoadjuvant Chemotherapy (NAC) Prior to Bladder-Sparing Trimodality Therapy (TMT) for Patients With Muscle-Invasive Bladder Cancer (MIBC).
Neoadjuvant chemotherapy followed by bladder-sparing treatment offered durable remission for some muscle-invasive bladder cancer patients over long term.
Neoadjuvant chemotherapy (NAC) followed by bladder-sparing trimodality therapy (TMT) is an emerging treatment option for selected patients with muscle-invasive bladder cancer (MIBC), but long-term outcome data remain lim. Prospective studies integrating novel systemic therapies and biomarkers, including ctDNA and urinary tumor DNA, may further optimize bladder-sparing approaches.
What the study was
- Study design
- Cohort study
- Population
- Cancer/disease patients
- Sample size
- 56
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Clinical genitourinary cancer
Why it surfaced
Matched topic(s): Early cancer detection. Study design: Cohort study. Score 7/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.